Across global biopharma organizations, additional Risk Minimisation Measures (aRMMs) represent some of the most compliance-critical obligations a pharmacovigilance team manages. And yet, for many organizations, the process of tracking aRMM implementation across affiliate networks still runs on email threads and spreadsheets.
The problem isn’t effort, it’s infrastructure.
The Challenge: Affiliate Complexity at Scale
Every affiliate market brings its own requirements, timelines, and regulatory obligations. What’s required in Germany may differ significantly from what’s expected in Japan or Brazil. A single aRMM program, such as a Dear Healthcare Professional communication, a controlled distribution scheme, or a patient alert card, can have dozens of regional variants, each with its own implementation deadlines and documentation requirements.
When you’re managing this across 20, 40, or 80+ affiliate markets, coordination doesn’t just become difficult, it becomes a systemic risk. The gaps between affiliates aren’t visible until an inspector asks you to demonstrate them.
The Manual Tracking Problem
Most pharmacovigilance teams managing aRMMs today rely on some combination of:
- Email chains with affiliate contacts
- Shared spreadsheets tracking implementation status
- Manual follow-ups and status check-ins
- Periodic reports assembled before audits or inspections
These approaches aren’t wrong — they reflect a genuine operational reality. But they create a critical vulnerability: fragmented visibility. When implementation status lives across inboxes and local files, there’s no single source of truth. And when a regulator asks for evidence of affiliate compliance on day one of an inspection, assembling that picture in real time is not a position any team wants to be in.
The Gap Between Having a Process and Demonstrating It
One of the most underappreciated risk factors in pharmacovigilance inspections is the delta between what a team has done and what they can prove they’ve done. Inspection findings don’t always reflect genuine compliance failures. Instead, they often reflect documentation and traceability failures.
If your affiliate in Spain completed their aRMM patient card distribution on time, but the record of that completion is buried in an email from six months ago, that accomplishment is effectively invisible at the point of inspection. The work was done. The risk was managed. But the audit trail doesn’t support it.
This is the visibility gap, and it’s where organizations get hurt.
What Centralized aRMM Oversight Looks Like
Closing this gap requires more than better spreadsheets. It requires a purpose-built system that maintains real-time visibility across your entire affiliate network and tracking every obligation, every implementation status, and every performance metric in one place.
With Orbit, pharmacovigilance teams can:
- Centralize aRMM tracking across all affiliate markets in a single platform
- Monitor implementation status at the obligation level — by region, by product, by deadline
- Generate inspection-ready reports that demonstrate compliance without manual assembly
- Maintain a complete audit trail of who did what, when, and where
- Proactively identify gaps before they become findings
The goal isn’t just operational efficiency — it’s inspection confidence. When every affiliate obligation is tracked, time-stamped, and reportable on demand, the gap between having a process and demonstrating it disappears.
A Question Worth Asking
How is your team currently keeping affiliate networks aligned on aRMM implementation? If the honest answer involves a lot of manual coordination and crossed fingers ahead of inspections, it may be time to look at what a purpose-built GvP tracking platform can do for your oversight posture.
Orbit is designed for exactly this challenge. It’s built for global biopharma teams that need visibility, traceability, and confidence across every affiliate market they operate in.
Get in touch with our team to see how Orbit supports aRMM oversight at scale.
